RecruitingPhase 1NCT06464588

A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

Studying Dilated cardiomyopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Emory University
Principal Investigator
William Mahle, MD
Emory University
Intervention
Allogeneic Neonatal mesenchymal stromal cells (nMSCs)(biological)
Enrollment
36 enrolled
Eligibility
4-30 years · All sexes
Timeline
20252027

Study locations (5)

Collaborators

The Marcus Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06464588 on ClinicalTrials.gov

Other trials for Dilated cardiomyopathy

Additional recruiting or active studies for the same condition.

See all trials for Dilated cardiomyopathy

← Back to all trials